Addex Therapeutics Ltd
ADXN
$7.10
-$0.2022-2.77%
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -51.22% | -52.25% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -47.06% | -52.55% | |||
| Cost of Revenue | -36.81% | 33.42% | |||
| Gross Profit | 31.47% | -2,007.69% | |||
| SG&A Expenses | -26.41% | -15.94% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -29.88% | -4.10% | |||
| Operating Income | 27.66% | -10.33% | |||
| Income Before Tax | -9.63% | -91.60% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -9.63% | -91.60% | |||
| Earnings from Discontinued Operations | -100.02% | 689.32% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -112.42% | 503.35% | |||
| EBIT | 27.66% | -10.33% | |||
| EBITDA | 24.45% | 3.10% | |||
| EPS Basic | -112.42% | 500.28% | |||
| Normalized Basic EPS | -9.80% | -88.89% | |||
| EPS Diluted | -116.01% | 500.28% | |||
| Normalized Diluted EPS | -86.67% | -11.11% | |||
| Average Basic Shares Outstanding | 0.00% | 0.79% | |||
| Average Diluted Shares Outstanding | -41.48% | 72.24% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
